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Should the Guideline Recommendations Be Revisited?*Manesh R. Patel, MD, E. Magnus Ohman, MDSEE PAGE 511T he early invasive strategy with cardiac cathe-terization within 72 h of onset of symptomshas now become standard-of-care in the ma-
jority of countries around the world for patients with
acute coronary syndromes (ACS). It is a Class 1B
recommendation in the latest American College of
Cardiology/American Heart Association practice
guidelines for non–ST-segment elevation (NSTE)
ACS and a Level 1A recommendation from the Euro-
pean Society of Cardiology (1,2). This very ﬁrm foun-
dation of recommendation was established by
several landmark studies carried out in the late
1990s and the early 2000s (3–6). In aggregate, these
prospective randomized trials provided ample evi-
dence that major cardiovascular endpoints such as
death and myocardial infarction were reduced with
an invasive strategy over a selective invasive strat-
egy. The RITA-3 (Third Randomised Intervention
Treatment of Angina) randomized trial provided a
unique insight into this, because the trial also demon-
strated reduced all-cause mortality at 5 years.
Furthermore, when these trials were combined into
a patient-level meta-analysis in patients who were
risk stratiﬁed, it became apparent that this strategy
was most beneﬁcial in the high-risk patient cohorts,
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istics. The majority of the trials also have reported
longer-term outcomes data, but none of them have
reported beyond 5 years.In this issue of the Journal, Henderson et al. (7)
report on the long-term mortality outcomes of the
RITA-3 trial at 10 years. This is a fascinating evalua-
tion of long-term data that is so rarely possible, but
it is facilitated by linking a national registry in the
United Kingdom with a clinical trial cohort. The
authors had previously reported the 5-year follow-up
data from the RITA-3 trial (8). In the current report,
the investigators use the ofﬁce of national statistics to
obtain all-cause mortality from 5 to 10 years following
the original randomization. They ﬁnd that the all-
cause mortality reduction of 24% seen at 5 years has
slowly dissipated by 10 years, with no statistical sig-
niﬁcance. The authors further stratify the results by
the post-discharge GRACE score and ﬁnd no clear
treatment effect by low-, intermediate-, or high-risk
categories. They also perform a multivariable model
that identiﬁes age, prior myocardial infarction or
heart failure, and extent of coronary disease as
important predictors of long-term mortality, but not
the randomization strategy. Given these results, the
authors conclude that we require further clinical
trials of contemporary interventional strategies in
patients with NSTE-ACS. These conclusions will likely
give clinicians and guideline committees pause as
they consider the current recommended strategies for
management of patients with NSTE-ACS. To under-
stand the results, we must consider both what we do
know for certain from the RITA-3 investigators’ report
and the limitations of the study.
What remain unknown are the long-term effects of
a routine invasive strategy on recurrent ischemia,
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522revascularization, and myocardial infarction. All of
these endpoints were reduced at 5 years and remain
important to patients and clinicians. This may in part
be due to the fact that the mortality endpoint from
5 to 10 years is evaluated through a national database
and not in the same fashion as during the trial. There
is also no information on revascularization during
follow-up beyond 5 years. However, through careful
analysis, they have explored the rate of revas-
cularizations up to 5 years and its potential effect on
later mortality. These ﬁndings do not provide any
further insight into why the mortality curves changed
from 5 to 10 years of follow-up.
A consideration is that the treatment of patients
with coronary artery disease is not static. Cardiologists
sometimes quickly adapt new treatment strategies
for perceived improvement in outcomes. One such
example is the rapid uptake of drug-eluting stents in
the early 2000s, which led to a quick adoption in a
largely off-label population (9). This ongoing change
in practice could also play a role in a cohort of patients
who were managed by a selective invasive approach;
because the information became known to the prac-
ticing community 5 years after the start of the trial,
patients who were readmitted later after the initial
completion of the trial may have been managed with a
more invasive approach. However, a more conserva-
tive approach may have been selected for those who
were already revascularized in the invasive arm (10).
Unfortunately, the subsequent revascularization
strategies beyond the 5-year time point in the RITA-3
trial are not known. The authors acknowledge this
limitation; yet, the data are actually of some interest
when the mortality curves are examined closely.
In the report, the authors have calculated the
mortality rates (per 100 person-years) in the 2 treat-
ment groups in 2-year intervals throughout the
10-year period. In the ﬁrst 4 years of the trial, the
investigators do not know the results of the 5-year
mortality outcomes, but they become known later
because of the publication showing a signiﬁcant
reduction in mortality after the initial 5 years of
follow-up. In examining the mortality curves, some
interesting features emerge. During the ﬁrst 4 years,
the annual mortality rate is 2.46 for the routine
invasive strategy versus 3.38 for the selective inva-
sive strategy. If one assumes that it took 1 to 2 years to
disseminate the early trial results after the 5-year
results, then examining the mortality rates at the
tail end of the trial would be important because pa-
tients who were largely managed selectively inva-
sively may have undergone more invasive treatment
strategies for their recurrent ACS event. In this re-
gard, the mortality rate per 100 person-years in thelast 2 years of the trial for the selective invasive group
is now substantially lower at 2.67 compared with the
early part of the trial. This suggests that something
changed in this cohort in the last 4 years of the
10-year follow-up period. However, the routine
invasive strategy had event rates at 3.49/100 person-
years, almost mimicking the event rate in the early
phase of the selective invasive group. Patients who
had already had their anatomy evaluated may in turn
be managed with less revascularization (10). Although
this remains speculation, it speaks to 2 issues:
namely, relatively a lack of power to detect important
mortality rates, but also an understanding that the
follow-up treatment strategies are an important part
of a trial and may affect subsequent outcomes.
So, what can the practicing physicians take from
these ﬁndings? First are the possible explanations for
observed long-term mortality in the RITA-3 trial. As
noted, it is not clear if this loss of mortality reduction
is due to attenuation of a direct treatment effect,
treatment crossovers over the long-term follow-up,
changing clinical therapeutics with improved anti-
platelet and antithrombotic therapies, or simply the
play of chance. Although each possibility may play a
role, it seemsmost likely that the signiﬁcant treatment
effect from the initial study, the widespread clinical
presentation of the trial ﬁndings, and guideline rec-
ommendations caused clinical practice to shift toward
more routine invasive care. This is what we would
hope happens with an active quality cycle in which
ﬁndings are incorporated into clinical practice (11).
These ﬁndings of RITA-3 can therefore be inter-
preted as an important milestone of understanding
the effect of an early invasive strategy on long-
term outcomes. As such, the trial suggests that the
beneﬁt observed initially may not be translated into a
longer beneﬁt. How much of this attenuation can be
ascribed to a change in practice pattern remains un-
clear. However, we should be heartened by the fact
that physicians may be using the latest clinical trial
data to improve the care for their patients with
ACS, and therefore, our ability to interpret late out-
comes may be heavily affected by the improving
physicians’ performance around guidelines and the
optimal care for patients with ACS. This is a very
positive message indeed if you are a patient, but it
makes it much harder if you are a researcher or
guidelines writer in the ﬁeld of cardiology.
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